# TB-500: research reference

For research use only. Checked November 1, 2026.

TB-500 is a research label that needs an exact identity specification. A 2024 analytical study uses TB-500 for the acetylated seven-residue fragment Ac-LKKTETQ. Other discussions connect the label with full-length thymosin beta-4, a different material. Findings from the full-length peptide cannot automatically be assigned to that fragment, its metabolites, or an unspecified commercial product. Check the sequence and modification before comparing papers.

## Identity
The fragment studied by Rahaman and colleagues is Ac-LKKTETQ, including an N-terminal acetyl modification. Full-length thymosin beta-4 is a 43-residue peptide. The sequence, terminal chemistry, molecular specification and analytical reference should resolve which material an experiment or catalog actually means; the words TB-500 alone do not resolve that distinction.

## Mechanism
The full-length thymosin beta-4 literature includes actin-related biology and cell-migration experiments. That context helps explain the interest in related fragments, but biological activity is not automatically preserved when a sequence is shortened or chemically modified.

Metabolism introduces another identity layer. A parent compound and a breakdown product can behave differently in an assay. A result attributed loosely to TB-500 may therefore require checking both the starting material and what was present during the measurement.

## Selected research
### The fragment and its metabolites were not interchangeable
Model: Analytical method development, in-vitro systems and rat samples

The 2024 study distinguished the Ac-LKKTETQ parent from metabolites and reported a wound-assay signal for one metabolite rather than the parent in its experiment.

Limitation: An assay result and metabolite profile do not establish a clinical effect or equivalence with full-length thymosin beta-4.

### Full-length thymosin beta-4 has a separate experimental record
Model: Rat skin-wound model and a keratinocyte migration assay

Malinda and colleagues reported changes in wound-associated endpoints and cell migration while studying thymosin beta-4.

Limitation: This was research on the full-length peptide, not a validation of every material sold under the TB-500 label.

## Open questions
- What exact material does a given supplier mean by TB-500? An incomplete label can prevent an otherwise careful literature comparison from answering the intended question.
- How much of an observed response is attributable to the starting peptide, a metabolite, or a feature of the assay? Analytical sampling and biological measurements need to be considered together.
- These two selected studies are not a direct head-to-head comparison of all possible fragments and full-length preparations. They should not be converted into an efficacy ranking or a claim about a specific supplier's lot.

## Storage and handling
Require sequence and modification details before selecting an analytical identity reference. A nominal mass without the molecular form and method context is incomplete.

The selected studies do not establish a universal shelf life for products labeled TB-500. Keep product-specific storage documentation separate from literature on metabolism or biological activity.

## Sources
- Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro (2024). https://pubmed.ncbi.nlm.nih.gov/38382158/
- Thymosin beta4 accelerates wound healing (1999). https://pubmed.ncbi.nlm.nih.gov/10469335/

For research use only. Primary abstracts and identifiers checked November 1, 2026. Identity ambiguity is central; do not relabel full-length thymosin beta-4 findings as fragment findings. No clinical or supplier-quality conclusion is made.